Work

Phase II trial of rucaparib (Without ADT) in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations (TRIUMPH).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.tps5095

Authors: Mark Christopher Markowski, Hao Wang, Rana Sullivan, Michael Haffner, Angelo M De Marzo, Tamara L. Lotan, Emmanuel S. Antonarakis

Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890574763

Cites:

Cited by: 7

Related to: 10